Phaseline

Companies › VivaTech International

VivaTech International: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 3 Phase 2; Immunology.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Autologous StroMed (adipose-derived regenerative cells) + Platelet Rich Plasma (
Autologous adipose tissue-derived regenerative cells combined with platelet-derived growth
–Phase 2Osteoarthritis–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT02844764Autologous StroMed (adipose-derived regenerative cells) + Platelet Rich Plasma (Phase 2OsteoarthritisImmunologyAug 2026
NCT02844738Autologous StroMed (adipose-derived regenerative cells) + Platelet Rich Plasma (Phase 2OsteoarthritisImmunologyAug 2026
NCT02844751Autologous StroMed (adipose-derived regenerative cells) + Platelet Rich Plasma (Phase 2OsteoarthritisImmunologyAug 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Aravax AltruBio Qu Biologics 4Moving Biotech Bluefin Biomedicine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.